Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2021

View Archived Issues

Researchers publish preclinical data on dimeric peptides as hair growth stimulants for alopecia

Researchers describe first dual IDO-1/2 inhibitor with notable activity in vitro and in vivo

Novel alkaloid derivatives with potential anticancer properties

New compounds containing morpholine moiety show promising antimicrobial activity

Researchers develop novel microbubble-based stem memory T cells targeting CD19

AMPK activator O-304 exerts type 2 diabetes remission in mice

TIPs show SARS-CoV-2 prophylactic and therapeutic activity, posing a barrier to resistance evolution

STK-009 provides control to maximize the efficacy of CART cell therapy in hematological tumors

New Ex20Ins mutant EGFR inhibitors decribed by Inventisbio Shanghai

Nanjing Ruijie Pharma identifies tyrosine-protein kinase SYK inhibitors

Wigen Biomedicine Technology discovers EGFR kinase inhibitors

New mutant EGFR inhibitors patented by Jiangsu Simcere Pharmaceutical R&D

Chonnam National University, Bio3s describe anticoronavirus protein compositions

Phages help to combat bacteria, reduce antibiotic use

Cyrus Biotechnology's SARS-CoV-2 decoy receptor retains efficacy against Omicron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...